胃食管反流藥物全球市場研究報告-2023-2030 年行業分析、規模、份額、增長、趨勢和預測

全球對胃食管反流藥物市場的需求將從 2022 年的 78 億美元擴大到 2030 年的近 124.5 億美元，預計 2023-2030 年研究期間的複合年增長率將達到 6.02%。

胃食管反流裝置 (GERD) 提供了另一種治療胃灼熱的方法。 GERD 是下食管括約肌 (LES) 鬆弛或功能障礙，導致胃液回流到食道，引起胃灼熱的一種病症。 壓力、食管裂孔疝、腹部肥胖和吸煙都是 GERD 的危險因素。 這些裝置的優勢在於它們提供了一種微創手術選擇來解決固有的解剖畸形。 此外，機器進行治療的醫療支持的發展正在逐漸普及。 然而，最大的缺點是它仍然需要臨床證明。

市場動態：

胃食管反流病患病率上升、生活方式改變和意識提高等主要因素預計將刺激胃食管反流病市場。 此外，隨著支持性臨床證據的增加，這些設備在微創手術中的應用正在穩步取得進展。 這在執行防止酸性和非酸性物質反流的手術時很有用，例如口腔筆記本電腦手術。 另一方面，由於用於治療胃酸反流的常用藥物已失去專利，市場可能會下滑。 然而，胃灼熱在全球範圍內呈上升趨勢，因此未來胃食管反流藥物市場可能會擴大。

這份研究報告解釋了波特的五力模型、市場吸引力分析和價值鏈分析。 這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。 此外，這些工具還提供了對全球胃食管反流藥物市場各個部分的全面評估。 胃食管反流藥物行業的發展和趨勢為這項研究提供了一種整體方法。

市場細分：

本部分按國家和地區提供詳細的細分數據，以幫助確定每種產品/服務的目標受眾和未來商機。

按藥物類型

• 抗酸劑
• H2 受體阻滯劑
• 質子泵抑製劑 (PPI)
• 促動力銀色

按地區分析：

本部分涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲、中東和非洲胃食管反流藥物市場當前和未來的需求。 此外，該報告重點關注所有主要地區每個單獨應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。 胃食管反流藥物市場的主要參與者是 AstraZeneca PLC、Eisai Co., Ltd.、GlaxoSmithKline PLC、Takeda Pharmaceutical Co. Ltd.、Takeda Pharmaceutical Company Limited、Johnson & Johnson K.K. 本節概述了競爭格局，包括各種戰略發展，例如主要併購、未來能力、合作夥伴關係、財務概覽、聯合研究、新產品開發和新產品發布。

內容

第一章前言

• 報告內容
  • 目的
  • 目標受眾
  • USP（獨特的銷售建議）及其提供的內容
• 調查範圍
• 調查方法
  • 市場調研流程
  • 市場研究方法

第 2 章執行摘要

• 市場亮點
• 全球市場概況

第3章胃食管反流藥-行業分析

• 簡介 - 市場動態
• 市場驅動因素
• 市場製約因素
• 機會
• 行業趨勢
• 波特的五力分析
• 市場吸引力分析
  • 按藥物類型進行的市場吸引力分析
  • 市場吸引力分析：按地區

第四章價值鏈分析

• 價值鏈分析
• 原材料分析
  • 原材料清單
  • 原材料製造商名單
  • 主要原材料價格走勢
• 潛在買家名單
• 營銷渠道
  • 直接營銷
  • 間接營銷
  • 市場發展趨勢

第 5 章 COVID-19 爆發的影響分析

第6章胃食管反流藥物全球市場分析：按藥物類型分列

• 藥物類型概述
• 過去和未來的數據
• 按藥物類型分析
• 抗酸劑
• H2 受體阻滯劑
• 質子泵抑製劑 (PPI)
• 促動力銀色

第7章全球胃食管反流藥物市場分析：分地區

• 區域展望
• 簡介
• 北美銷售分析
  • 概覽、歷史和預測銷售分析
  • 北美各部門的銷售分析
  • 北美銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史和預測銷售分析
  • 按細分市場進行的歐洲銷售分析
  • 按國家/地區劃分的歐洲銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 意大利銷售分析
  • 俄羅斯銷售分析
  • 其他歐洲銷售分析
• 亞太地區銷售分析
  • 概覽、歷史和預測銷售分析
  • 亞太地區各部門的銷售分析
  • 亞太國家/地區銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本的銷售分析
  • 韓國銷售分析
  • 澳大利亞銷售分析
  • 其他亞太地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史和預測銷售分析
  • 拉丁美洲各部門的銷售分析
  • 拉丁美洲國家/地區的銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利的銷售分析
  • 其他拉丁美洲銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史和預測銷售分析
  • 中東和非洲各細分市場的銷售額分析
  • 中東和非洲國家/地區的銷售分析
  • 沙特阿拉伯銷售分析
  • 阿聯酋銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 其他中東和非洲銷售分析

第八章胃食管反流藥企業競爭格局

• 胃食管反流藥物市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他擴展

第九章公司簡介

• 頂級公司的市場份額分析
• 市場集中度
• 阿斯利康公司
  • 公司簡介
  • 企業收入
  • 產品介紹
  • 近期趨勢
• 衛材有限公司
  • 公司簡介
  • 企業收入
  • 產品介紹
  • 近期趨勢
• 葛蘭素史克公司
  • 公司簡介
  • 企業收入
  • 產品介紹
  • 近期趨勢
• 武田製藥有限公司
  • 公司簡介
  • 企業收入
  • 產品介紹
  • 近期趨勢
• 強生公司。
  • 公司簡介
  • 企業收入
  • 產品介紹
  • 近期趨勢

注意：公司簡介中的財務信息和近期發展基於可用信息，可能不包括私營公司。

The global demand for Gastroesophageal Reflux Disease Therapeutics Market is presumed to reach the market size of nearly USD 12.45 BN by 2030 from USD 7.8 BN in 2022 with a CAGR of 6.02% under the study period 2023 - 2030.

Gastroesophageal reflux disease therapeutics device (GERD) provides an alternate method for treating heartburn. It is essentially a condition wherein the lower esophageal sphincter (LES) relaxes or fails to function effectively, allowing stomach liquids to reflux back into the oesophagus, thus, causing heartburn. Stress, hiatal hernia, abdominal obesity, and smoking are all risk factors for GERD. These devices are advantageous as they provide an option for minimally invasive surgery to address inherent anatomical deformities. They are slowly gaining ground with evolving supportive medical proofs for machines to carry out the treatment. However, their biggest disadvantage is that they still need to be clinically proven.

Market Dynamics:

Major factors such as the rising prevalence of gastrointestinal reflux diseases, changing lifestyles, and increasing awareness are expected to fuel the gastroesophageal reflux disease therapeutics market. Further, using these devices for minimally invasive procedures is steadily gaining traction with growing supportive clinical evidence. This will help perform procedures, such as transoral fundoplication, which prevent acid and non-acid contents' reflux. On the downside, the market may experience a decline due to the patent expiration of popular medications used to treat acid reflux diseases. Nonetheless, the gastroesophageal reflux disease therapeutics market is set to expand in the future years as heartburn prevalence increases globally.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gastroesophageal reflux disease therapeutics. The growth and trends of gastroesophageal reflux disease therapeutics industry provide a holistic approach to this study.

Market Segmentation:

This section of the gastroesophageal reflux disease therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

• Antacids
• H2 Receptor Blockers
• Proton Pump Inhibitors (PPIs)
• Pro-Kinetic Agents

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Gastroesophageal Reflux Disease Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gastroesophageal reflux disease therapeutics market include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., and Johnson & Johnson. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Type
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET ANALYSIS BY DRUG TYPE

• 6.1 Overview by Drug Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Drug Type
• 6.4 Antacids Historic and Forecast Sales by Regions
• 6.5 H2 Receptor Blockers Historic and Forecast Sales by Regions
• 6.6 Proton Pump Inhibitors (PPIs) Historic and Forecast Sales by Regions
• 6.7 Pro-kinetic Agents Historic and Forecast Sales by Regions

7 . GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS COMPANIES

• 8.1. Gastroesophageal Reflux Disease Therapeutics Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. AstraZeneca PLC
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Eisai Co. Ltd.
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. GlaxoSmithKline PLC
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Takeda Pharmaceutical Co. Ltd.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Johnson & Johnson.
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Type (USD MN)
• Antacids Market Sales by Geography (USD MN)
• H2 Receptor Blockers Market Sales by Geography (USD MN)
• Proton Pump Inhibitors (PPIs) Market Sales by Geography (USD MN)
• Pro-kinetic Agents Market Sales by Geography (USD MN)
• Global Gastroesophageal Reflux Disease Therapeutics Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Gastroesophageal Reflux Disease Therapeutics Report
• Market Research Process
• Market Research Methodology
• Global Gastroesophageal Reflux Disease Therapeutics Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Type
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Type (USD MN)
• Antacids Market Sales by Geography (USD MN)
• H2 Receptor Blockers Market Sales by Geography (USD MN)
• Proton Pump Inhibitors (PPIs) Market Sales by Geography (USD MN)
• Pro-kinetic Agents Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.